title: [Bone marrow suppression in gynecological patients with malignant tumor treated with combination chemotherapy cyclophosphamide, pirarubicin and cisplatin].
abstract: We treated 14 patients with cyclophosphamide, adriamycin and cisplatin (CAP), and 16 patients with cyclophosphamide, Pirarubicin and cisplatin (CTP). Hematological changes in the peripheral blood were compared in the two groups to determine whether there was any difference in bone marrow suppression. 1) The lowest leukocyte counts were similar in the two groups. The leukocyte count reached its nadir at 11.6 +/- 2.1 days in the CTP group and at 15.1 +/- 2.8 days in the CAP group, a significant difference (p less than 0.01). 2) The leukocyte count recovered rapidly in the CTP group and was significantly higher (p less than 0.01) at 3 to 4 weeks than in the CAP group, and it returned to the pretreatment level in the CTP group in the fourth week. 3) The platelet count reached its lowest level in the second week in both groups. In the CTP group, it was significantly higher (p less than 0.01) than in the CAP group. 4) Reticulocyte count reached its lowest level in the first week in both groups, and then started increasing. 5) In the CTP group, a course of treatment was 28.0 +/- 2.3 days and it was 29.5 +/- 2.3 days in the CAP group. In 28% of the CPA group, it took 30 days or more for the leukocyte count to return to normal after one course, while none of the CTP group did the leukocyte count remain low for 30 days. These results show that CTP causes more rapid bone marrow suppression (particularly leukocytopenia) than CAP, does but that a recovery is more rapid with CTP. These CTP may be a better form of treatment than CAP.
authors.affiliation: Dept. of Obstetrics and Gynecology, Osaka Medical College.
authors.forename: S
authors.initials: S
authors.lastname: Kozaki
authors.forename: Y
authors.initials: Y
authors.lastname: Yanagawa
authors.forename: M
authors.initials: M
authors.lastname: Ueki
authors.forename: O
authors.initials: O
authors.lastname: Sugimoto
authors.forename: T
authors.initials: T
authors.lastname: Okazaki
authors.forename: M
authors.initials: M
authors.lastname: Saeki
authors.forename: H
authors.initials: H
authors.lastname: Nomura
authors.forename: T
authors.initials: T
authors.lastname: Kanda
authors.forename: E
authors.initials: E
authors.lastname: Iwai
authors.forename: Y
authors.initials: Y
authors.lastname: Miyawaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D002945:Cisplatin